Mast cells and basophils are granulated metachromatic cells which possess complex and partially overlapping roles in acquired and innate immunity, including both effector and regulatory activities. Mast cells and basophils cooperate in exacerbating and/or modulating inflammation as well as in mediating subsequent tissue repair. Mast cells release a series of potent proangiogenic molecules during inflammation that stimulate vessel sprouting and new vessel formation. Recent data suggest that basophils may also play a role in inflammation-related angiogenesis, principally but not exclusively through the expression of several forms of vascular endothelial growth factors and their receptors. This review focuses on the potential cooperative link between mast cells and basophils in promoting angiogenesis during allergic inflammation. We discuss the multifaceted roles of mast cells and basophils in inflammatory mechanisms of allergic diseases and whether these cells can be both source and target of proangiogenic mediators.

Keywords:
Allergic inflammation, Angiogenesis, Basophils, Mast cells
1.
Gribaldeston MA, Metz M, Yu M, Tsai M, Galli SJ: Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 2006;18:751–760.
2.
Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8:478–486.
3.
Metz M, Siebenhaar F, Maurer M: Mast cell functions in the innate skin immune system. Immunobiology 2008;213:251–260.
4.
Patella V, Giuliano A, Bouvet JP, Marone G: Endogenous superallergen protein Fv induces IL-4 secretion from human FcεR+ cells through interaction with the VH3 region of IgE. J Immunol 1998;161:5647–5655.
5.
Patella V, Florio G, Petraroli A, Marone G: HIV-1 gp120 induces IL-4 and IL-13 release from FcεR+ cells through interaction with the VH3 region of IgE. J Immunol 2000;164:589–595.
6.
Sayed BA, Christy A, Quirion MR, Brown MA: The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 2008;26:705–739.
7.
Galli SJ, Tsai M: Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008;49:7–19.
8.
Ehrlich P: Beiträge zur Theorie und Praxis der histologischen Färbung; thesis, Leipzig University, 1878.
9.
Ehrlich P: Beiträge zur Kenntnis der granulierten Bindgewebszellen und der eosinophilen Leukozyten. Arch Anat Physiol 1879;3:166–169.
10.
Dvorak AM: Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 2005;53:1043–1070.
11.
Okayama Y, Kawakami T: Development, migration and survival of mast cells. Immunol Res 2006;34:97–115.
12.
Ashman LK: The biology of stem-cell factor and its receptor c-kit. Int J Biochem Cell Biol 1999;31:1037–1051.
13.
Arock M, Schneider E, Boissan M, Tricottet V, Dy M: Differentiation of human basophils: an overview of recent advances and pending questions. J Leukoc Biol 2002;71:557–564.
14.
Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, Hinterberger W, Lechner K, Maurer D, Bettelheim P: Interleukin-3 is a differentiation factor for human basophils. Blood 1989;73:1763–1769.
15.
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CMM, Tsai M: Mast cells as ‘tunable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749–786.
16.
Karasuyama H, Mukai K, Tsujimura Y, Obata K: Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 2009;9:9–13.
17.
Mochizuki A, McEuen AR, Buckley MG, Walls AF: The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation. J Allergy Clin Immunol 2003;112:102–108.
18.
Li L, Li Y, Reddel SW, Cherrian M, Friend DS, Stevens RL, Krilis SA: Identification of basophilic cells that express mast cell granule proteases in the peripheral blood of asthma, allergy and drug-reactive patients. J Immunol 1998;161:5079–5086.
19.
Sullivan BM, Locksley RM: Basophils: a nonredundant contributor to host immunity. Immunity 2009;30:12–20.
20.
Gibbs BF: Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med 2005;5:43–49.
21.
Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L: The biology of IgE and the basis of allergic disease. Annu Rev Immunol 2003;21:579–628.
22.
Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–S494.
23.
Min B, Prout M, Hu-Li J, Zhu J, Jankovic D, Morgan ES, Urban JF Jr, Dvorak AM, Finkelman FD, LeGros G, Paul WE: Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J Exp Med 2004;200:507–517.
24.
MacGlashan D: IgE receptor and signal transduction in mast cells and basophils. Curr Opin Immunol 2008;20:1–7.
25.
Kawakami T, Galli SJ: Regulation of mast cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773–786.
26.
Malbec O, Daëron M: The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 2007;217:206–221.
27.
Tsujimura Y, Obata K, Mukai K, Shindou H, Yoshida M, Nishikado H, Kawano Y, Minegishi Y, Shimizu T, Karasuyama H: Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 2008;28:581–589.
28.
Komiya A, Nagase H, Okugawa S, et al: Expression and function of Toll-like receptors in human basophils. Int Arch Allergy Immunol 2006;140(suppl 1):23–27.
29.
Bachelet I, Levi-Schaffer F: Mast cells as effector cells: a costimulating question. Trends Immunol 2007;28:360–365.
30.
Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy JY: Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993;365:340–343.
31.
Yanagihara Y, Kajiwara K, Basaki Y, Ikizawa K, Ebisawa M, Ra C, Tachimoto H, Saito H: Cultured basophils but not cultured mast cells induce human IgE synthesis in B cells after immunologic stimulation. Clin Exp Immunol 1998;111:136–143.
32.
Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ: Mast cells in promotion and limitation of chronic inflammation. Immunol Rev 2007;217:304–328.
33.
Gilfillan AM, Tkaczyk C: Integrated signalling pathways for mast cell activation. Nat Rev Immunol 2006;6:218–230.
34.
Echtenacher B, Männel DN, Hueltner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature1996;381:75–77.
35.
Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996;381:77–80.
36.
Piliponski AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner PR, Wada E, Wada K, Zacharias S, Mohanasundaram UM, Faix JD, Abrink M, Pejler G, Pearl RG, Tsai M, Galli SJ: Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 2008;14:392–398.
37.
Benoist C, Mathis D: Mast cells in autoimmune disease. Nature 2002;420:875–878.
38.
de Paulis A, Prevete N, Fiorentino I, Walls AF, Curto M, Petraroli A, Castaldo V, Ceppa P, Fiocca R, Marone G: Basophils infiltrate human gastric mucosa at sites of Helicobacter pylori infection, and exhibit chemotaxis in response to H. pylori-derived peptide Hp(2-20). J Immunol 2004;172:7734–7743.
39.
Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 2008;454:445–454.
40.
Spitzauer S, Huss-Marp J, Brockow K, Darsow U, Behrendt H, Ring J, Kricek F, Valent P, Valenta R: Mast cell-derived proteases control allergic inflammation through cleavage of IgE. J Allergy Clin Immunol 2008;121:197–202.
41.
Estelle F, Simons R: Anaphylaxis. J Allergy Clin Immunol 2008;121(suppl):402s–407s.
42.
Marshall JS, McCurdy JD, Olynych T: Toll-like receptor-mediated activation of mast cells: implications for allergic diseases? Int Arch Allergy Immunol 2003;132:87–97.
43.
Vines CM, Prossnitz ER: Mechanisms of G protein-coupled receptor-mediated degranulation. FEMS Microbiol Lett 2004;236:1–6.
44.
Schroeder JT, MacGlashan DW Jr, Lichtenstein LM: Human basophils: mediator release and cytokine production. Adv Immunol 2001;77:93–122.
45.
Min B, Paul WE: Basophils and type 2 immunity. Curr Opin Hematol 2008;15:59–63.
46.
Voehringer D, Shinkai K, Locksley RM: Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004;20:267–277.
47.
Holgate ST: Airway inflammation and remodeling in asthma: current concepts. Mol Biotechnol 2002;22:179–189.
48.
Mukai K, Matsuoka K, Taya C, Suzuki H, Yokozeki H, Nishioka K, Hirokawa K, Etori M, Yamashita M, Kubota T, Minegishi Y, Yonekawa H, Karasuyama H: Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. Immunity 2005;23:191–202.
49.
Marone G, Triggiani M, Genovese A, de Paulis AD: Role of human mast cells and basophils in bronchial asthma. Adv Immunol 2005;88:97–160.
50.
Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D: Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65–78.
51.
Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, Theoharides TC: Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005;174:7665–7675.
52.
Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F: Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005;116:531–536.
53.
Koshino T, Arai Y, Miyamoto Y, Sano Y, Itami M, Teshima S, Hirai K, Takaishi T, Ito K, Morita Y: Airway basophil and mast cell density in patients with bronchial asthma: relationship to bronchial hyperresponsiveness. J Asthma 1996;33:89–95.
54.
Irani AM, Huang C, Xia HZ, Kepley C, Nafie A, Fouda ED, Craig S, Zweiman B, Schwartz LB: Immunohistochemical detection of human basophils in late-phase skin reactions. J Allergy Clin Immunol 1998;101:354–362.
55.
Macfarlane AJ, Kon OM, Smith SJ, Zeibecoglou K, Khan LN, Barata LT, McEuen AR, Buckley MG, Walls AF, Meng Q, Humbert M, Barnes NC, Robinson DS, Ying S, Kay AB: Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol 2000;105:99–107.
56.
Obata K, Mukai K, Tsujimura Y, Ishiwata K, Kawano Y, Minegishi Y, Watanabe N, Karasuyama H: Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood 2007;110:913–920.
57.
Risau W: Mechanisms of angiogenesis. Nature 1997;386:671–674.
58.
Dunnill MS: The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 1960;13:27–33.
59.
Li X, Wilson JM: Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997;156:229–233.
60.
Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH: Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999;54:289–295.
61.
McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001;164:S39–S45.
62.
Wilson J: The bronchial microcirculation in asthma. Clin Exp Allergy 2000;30:51–53.
63.
Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S: CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004;25:201–209.
64.
Mehrad B, Keane MP, Strieter RM: Chemokines as mediators of angiogenesis. Thromb Haemost 2007;97:755–762.
65.
Zaja-Milatovic S, Richmond A: CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol 2008;23:1399–1407.
66.
Keeley EC, Mehrad B, Strieter RM: Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008;28:1928–1936.
67.
Salcedo R, Oppenheim JJ: Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interactions, a key regulator of endothelial cell responses. Microcirculation 2003;10:359–370.
68.
Min B, Le Gros G, Paul WE: Basophils: a potential liaison between innate and adaptive immunity. Allergol Int 2006;55:99–104.
69.
Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P: Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol 2005;77:759–766.
70.
Watanabe M, Satoh T, Yamamoto Y, Kanai Y, Karasuyama H, Yokozeki H: Overproduction of IgE induces macrophage-derived chemokine (CCL22) secretion from basophils. J Immunol 2008;181:5653–5659.
71.
Dvorak AM: Mast cell-derived mediators of enhanced microvascular permeability, vascular permeability factor/vascular endothelial growth factor, histamine, and serotonin, cause leakage of macromolecules through a new endothelial cell permeability organelle, the vesiculo-vacuolar organelle. Chem Immunol Allergy 2005;85:185–204.
72.
de Paulis A, Prevete N, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, Ribatti D, Walls AF, Marone G: Expression and functions of vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006;177:7322–7331.
73.
Textor B, Licht AH, Tuckermann JP, Jessberger R, Razin E, Angel P, Schorpp-Kistner M, Hartenstein B: JunB required for IgE-mediated degranulation and cytochine release of mast cells. J Immunol 2007;179:6873–6880.
74.
Abdel-Majid RM, Marshall JS: Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 2004;172:1227–1236.
75.
Cao L, Curtis CL, Theoharides TC: Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 2006;69:998–1006.
76.
Norrby K: Mast cells and angiogenesis. APMIS 2002;110:355–371.
77.
Ribatti D, Belloni AS, Nico B, Sala G, Longo V, Mangieri D, Crivellato E, Nussdorfer GG: Tryptase- and leptin-positive mast cells correlate with vascular density in uterine leiomyomas. Am J Obstet Gynecol 2007;196:470–477.
78.
Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H: Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645–2649.
79.
Marone G, Triggiani M, de Paulis A: Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol 2005;26:25–31.
80.
Pettipher R, Hansel TT: Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect 2008;21:317–322.
81.
Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP: Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003;305:1212–1221.
82.
Lippert U, Moeller A, Welker P, Artuc M, Henz BM: Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9:118–124.
83.
Mellor EA, Maekawa A, Austen KF, Boyce JA: Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001;98:7964–7969.
84.
Gauvreau GM, Plitt JR, Baatjes A, MacGlashan DW: Expression of functional cysteinyl leukotriene receptors by human basophils. J Allergy Clin Immunol 2005;116:80–87.
85.
Rose CE Jr, Sung SS, Fu SM: Significant involvement of CCL2 (MAP-1) in inflammatory disorders of the lung. Microcirculation 2003;10:273–288.
86.
Fureder W, Agis H, Sperr WR, Lechner K, Valent P: The surface membrane antigen phenotype of human blood basophils. Allergy 1994;49:861–865.
87.
Sillaber C, Baghestanian M, Hofbauer R, Virgolini I, Bankl HC, Füreder W, Agis H, Willheim M, Leimer M, Scheiner O, Binder BR, Kiener HP, Bevec D, Fritsch G, Majdic O, Kress HG, Gadner H, Lechner K, Valent P: Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem 1997;272:7824–7832.
88.
de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P: Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol 2004;173:7734–7743.
89.
Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653–660.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.